Last reviewed · How we verify
IV meloxicam
At a glance
| Generic name | IV meloxicam |
|---|---|
| Sponsor | University of Miami |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Pruritus
- Hypotension
- Constipation
- Pyrexia
- Dizziness
- Hypoxia
- Hypokalemia
- Headache
- Urinary retention
- Ileus
Key clinical trials
- Phase 2 Herniorrhaphy Study for Opioid Elimination (PHASE2)
- Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects (PHASE1)
- Pre vs Post Block in Total Knee Arthroplasty (TKA) (PHASE4)
- Meloxicam for Pain Management After Total Joint Arthroplasty (TJA) (PHASE3)
- A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery (NA)
- Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery (PHASE4)
- Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery (PHASE2)
- Evaluation of N1539 Following Major Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV meloxicam CI brief — competitive landscape report
- IV meloxicam updates RSS · CI watch RSS
- University of Miami portfolio CI